Literature DB >> 19430732

Role of diffusion- and perfusion-weighted MR imaging for brain tumour characterisation.

L Rizzo1, S Greco Crasto, P Garcia Moruno, P Cassoni, R Rudà, R Boccaletti, M Brosio, R De Lucchi, C Fava.   

Abstract

PURPOSE: This study was undertaken to correlate apparent diffusion coefficient (ADC) and relative regional cerebral blood volume (rrCBV) to histological findings in a large series of patients with primary or secondary brain tumours to evaluate diffusion-weighted (DWI) and perfusion-weighted (PWI) imaging in the characterisation of cerebral tumors.
MATERIALS AND METHODS: Ninety-eight patients with cerebral tumours, 46 of which were primary (seven grade 0-I, nine low-grade gliomas, two gliomatosis cerebri, nine lymphomas and 19 high-grade gliomas) and 52 secondary, underwent conventional magnetic resonance (MR) imaging completed with DWI and dynamic contrast susceptibility PWI. Both ADC and rrCBV were calculated on a workstation by using Functool 2 software. Student's t test was used to determine any statistically significant differences in the ADC and rrCBV values.
RESULTS: Seventeen of 98 tumours were cystic or necrotic (12/17 hypointense and 5/17 hyperintense on DWI); the ADC value of hyperintense cystic areas was 0.97+/-0.23x10(-3) mm2/s. The ADC value of solid tumours varied between 0.64 and 3.5x10(-3) mm2/s. The rrCBV value was 1.4 (sigma 0.66) in low-grade gliomas; 1.22 (sigma 0.25) in lymphomas; 4.5 (sigma 0.85) in grade III gliomas; 3.18 (sigma 1.26) in grade IV gliomas and 2.53 (sigma 1.6) in metastases.
CONCLUSIONS: DWI has an important role in the differential diagnosis of cystic cerebral masses but not in tumour characterisation. PWI is helpful in differentiating high-from low-grade gliomas and lymphomas from high-grade gliomas.

Entities:  

Mesh:

Year:  2009        PMID: 19430732     DOI: 10.1007/s11547-009-0401-y

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  30 in total

Review 1.  Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging.

Authors:  Soonmee Cha; Edmond A Knopp; Glyn Johnson; Stephan G Wetzel; Andrew W Litt; David Zagzag
Journal:  Radiology       Date:  2002-04       Impact factor: 11.105

2.  Cerebral MR perfusion imaging: first clinical application of a 1 M gadolinium chelate (Gadovist 1.0) in a double-blinded randomized dose-finding study.

Authors:  T Benner; P Reimer; G Erb; G Schuierer; S Heiland; C Fischer; V Geens; K Sartor; M Forsting
Journal:  J Magn Reson Imaging       Date:  2000-09       Impact factor: 4.813

Review 3.  MR perfusion imaging: a tool for more than stroke.

Authors:  Michael Forsting; Johannes Weber
Journal:  Eur Radiol       Date:  2004-05       Impact factor: 5.315

4.  Value of diagnosis and differential diagnosis of MRI and MR spectroscopy in gliomatosis cerebri.

Authors:  Aihong Yu; Kuncheng Li; Hongli Li
Journal:  Eur J Radiol       Date:  2006-08       Impact factor: 3.528

5.  Evaluation of different cerebral mass lesions by perfusion-weighted MR imaging.

Authors:  Bahattin Hakyemez; Cuneyt Erdogan; Naile Bolca; Nalan Yildirim; Gokhan Gokalp; Mufit Parlak
Journal:  J Magn Reson Imaging       Date:  2006-10       Impact factor: 4.813

Review 6.  Value of 1.0- M gadolinium chelates: review of preclinical and clinical data on gadobutrol.

Authors:  Bernd Tombach; Walter Heindel
Journal:  Eur Radiol       Date:  2002-02-21       Impact factor: 5.315

7.  Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected].

Authors:  Michael H Lev; Yelda Ozsunar; John W Henson; Amjad A Rasheed; Glenn D Barest; Griffith R Harsh; Markus M Fitzek; E Antonio Chiocca; James D Rabinov; Andrew N Csavoy; Bruce R Rosen; Fred H Hochberg; Pamela W Schaefer; R Gilberto Gonzalez
Journal:  AJNR Am J Neuroradiol       Date:  2004-02       Impact factor: 3.825

8.  Differential MRI diagnosis between brain abscesses and necrotic or cystic brain tumors using the apparent diffusion coefficient and normalized diffusion-weighted images.

Authors:  Lydie Nadal Desbarats; Sandra Herlidou; Giovanni de Marco; Catherine Gondry-Jouet; Daniel Le Gars; Hervé Deramond; Ilana Idy-Peretti
Journal:  Magn Reson Imaging       Date:  2003-07       Impact factor: 2.546

9.  Contribution of dynamic contrast MR imaging to the differentiation between dural metastasis and meningioma.

Authors:  S Kremer; S Grand; C Rémy; B Pasquier; A L Benabid; S Bracard; J F Le Bas
Journal:  Neuroradiology       Date:  2004-06-30       Impact factor: 2.804

10.  Diffusion-Weighted Magnetic Resonance Imaging and ADC Maps in the Diagnosis of Intracranial Cystic or Necrotic Lesions. A Retrospective Study on 49 Patients.

Authors:  S Greco Crasto; R Soffietti; R Rudà; P Cassoni; A Ducati; O Davini; R De Lucchi; L Rizzo
Journal:  Neuroradiol J       Date:  2007-12-31
View more
  15 in total

1.  Diagnostic performance of DWI for differentiating primary central nervous system lymphoma from glioblastoma: a systematic review and meta-analysis.

Authors:  Xiaoyang Lu; Weilin Xu; Yuyu Wei; Tao Li; Liansheng Gao; Xiongjie Fu; Yuan Yao; Lin Wang
Journal:  Neurol Sci       Date:  2019-01-31       Impact factor: 3.307

Review 2.  Accuracy of percentage of signal intensity recovery and relative cerebral blood volume derived from dynamic susceptibility-weighted, contrast-enhanced MRI in the preoperative diagnosis of cerebral tumours.

Authors:  Ananya Chakravorty; Timothy Steel; Joga Chaganti
Journal:  Neuroradiol J       Date:  2015-10-16

3.  Magnetic resonance imaging of solitary brain metastases: main findings of nonmorphological sequences.

Authors:  S Gaudino; G M Di Lella; R Russo; V S Lo Russo; F Piludu; F R Quaglio; M R Gualano; C De Waure; C Colosimo
Journal:  Radiol Med       Date:  2012-06-28       Impact factor: 3.469

4.  Diffusion-weighted imaging in acute demyelinating myelopathy.

Authors:  Chiara Zecca; Carlo Cereda; Stephan Wetzel; Silvia Tschuor; Claudio Staedler; Francesco Santini; Navarajah Nadarajah; Claudio L Bassetti; Claudio Gobbi
Journal:  Neuroradiology       Date:  2011-07-09       Impact factor: 2.804

5.  Perfusion computed tomography assessments of peri-enhancing brain tissue in high-grade gliomas.

Authors:  A Stecco; F Fabbiano; P Amatuzzo; E Cignini; M Brambilla; L Masini; M Krengli; A Carriero
Journal:  Radiol Med       Date:  2012-08-08       Impact factor: 3.469

6.  DTI and PWI analysis of peri-enhancing tumoral brain tissue in patients treated for glioblastoma.

Authors:  Alessandro Stecco; Carla Pisani; Raffaella Quarta; Marco Brambilla; Laura Masini; Debora Beldì; Sara Zizzari; Rita Fossaceca; Marco Krengli; Alessandro Carriero
Journal:  J Neurooncol       Date:  2010-07-25       Impact factor: 4.130

7.  Dynamic susceptibility contrast (DSC) perfusion MRI in differential diagnosis between radionecrosis and neoangiogenesis in cerebral metastases using rCBV, rCBF and K2.

Authors:  Mario Muto; Giulia Frauenfelder; Rossana Senese; Fabio Zeccolini; Emiliano Schena; Francesco Giurazza; Hans Rolf Jäger
Journal:  Radiol Med       Date:  2018-03-05       Impact factor: 3.469

Review 8.  High-relaxivity contrast-enhanced magnetic resonance neuroimaging: a review.

Authors:  Frederik L Giesel; Amit Mehndiratta; Marco Essig
Journal:  Eur Radiol       Date:  2010-06-23       Impact factor: 5.315

9.  Crohn's disease of the small bowel: evaluation of ileal inflammation by diffusion-weighted MR imaging and correlation with the Harvey-Bradshaw index.

Authors:  Pietro Valerio Foti; Renato Farina; Maria Coronella; Stefano Palmucci; Noemi Ognibene; Pietro Milone; Cristina Conti Bellocchi; Leonardo Samperi; Gaetano Inserra; Andrea Laghi; Giovanni Carlo Ettorre
Journal:  Radiol Med       Date:  2015-02-04       Impact factor: 3.469

Review 10.  Perfusion MRI as a diagnostic biomarker for differentiating glioma from brain metastasis: a systematic review and meta-analysis.

Authors:  Chong Hyun Suh; Ho Sung Kim; Seung Chai Jung; Choong Gon Choi; Sang Joon Kim
Journal:  Eur Radiol       Date:  2018-04-04       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.